Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of Nanostart-holding MagForce AG

Abstract:
The Supervisory Board of Nanostart-holding Magforce AG (Frankfurt, Xetra: MF6), a leading medical device company in the field of oncology, has appointed Dr. Ben J. Lipps, former CEO and Chairman of Fresenius Medical Care, as Chairman of the Management Board and Chief Executive Officer of the company starting September 2013.

Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of Nanostart-holding MagForce AG

Berlin / Frankfurt Germany | Posted on June 17th, 2013

While serving as Chairman and CEO of Magforce, Ben Lipps will continue his consultantship with Fresenius Medical Care. The current management board members of Magforce Prof. Dr. Hoda Tawfik (Chief Developement & Medical Officer) and Christian von Volkmann (Chief Financial Officer) remain in their respective position.

Dr. Ben J. Lipps became Chairman and Chief Executive Officer of the Management Board of Fresenius Medical Care in May 1999. In December 2012, he stepped down as Chairman of the Management Board and CEO. Dr. Lipps led the research team that developed the first commercial hollow fiber artificial kidney at the end of the 1960's. Today over two million dialysis patients rely on hollow fiber dialyzers for life sustaining treatments.

Norbert Neef, Chairman of the Supervisory Board of MagForce, comments: "MagForce is very proud to have attracted a former DAX 30 CEO as addition to MagForce´s management team. Dr. Lipps will help us harvesting the full potential of our great IP. Based on the already existing regulatory approval for our NanoTherm® Therapy for all forms of brain cancer we are confident to be able to develop MagForce into a global medical device company successfully targeting the treatment of multiple cancer forms."

Ben Lipps comments: "MagForce is a most interesting opportunity in the medical device and pharma world. Globally, over two million patients are diagnosed with brain, head & neck, and prostate cancers each year. Clearly, the NanoTherm® Therapy being developed by MagForce AG can be applied as an adjunct or as a monotherapy to assist in the treatment regiments for these solid tumors. NanoTherm® Therapy has regulatory approval in 27 European countries already. I am looking forward to work with the very competent and highly motivated management team at MagForce. Our focus will be to advance this therapy to the next level with its widespread commercialization and to building a global player in the area of cancer treatment for the good of patients".

Dr. Ben J. Lipps became Chairman and Chief Executive Officer of the Management Board of Fresenius Medical Care in May 1999. In December 2012 he stepped down as Chairman of the Management Board and CEO. During his term, Fresenius Medical Care´s sales tripled from 3.8 to 12.8 billion dollars, and the annual net profit grew 6 times to 1.1 billion dollars.

He was also Chief Executive Officer of Fresenius Medical Care North America until February 2004. He was President, Chief Executive Officer, Chief Operating Officer and a director of Fresenius USA from October 1989 through February 2004, and served in various capacities with Fresenius USA's predecessor from 1985 through 1989.

He earned his master's and doctoral degrees at the Massachusetts Institute of Technology in chemical engineering. Before joining the Fresenius Group in 1985, Dr. Lipps held several research management positions in various companies, among them with DOW Chemical.

####

About Nanostart AG
Nanostart AG is a leading nanotechnology venture capital company. The company invests venture capital (VC) in promising young nanotechnology companies. Nanostart invests globally and at different phases of development. Emphasis of investments is on especially innovative industries such as cleantech, life sciences, and IT/electronics. Nanostart invests either directly in nanotechnology companies or through a regional nanotechnology fund. The headquarters of Nanostart AG is in Frankfurt, Germany.

About MagForce

MagForce AG is a leading medical technology company in the field of nanomedicine in oncology. The Company's proprietary, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm®, NanoPlan®, and NanoActivator™ are trademarks of MagForce AG in selected countries. For more information, please visit www.magforce.com

Disclaimer

This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within Canada, Australia, or Japan.

For more information, please click here

Contacts:
Nanostart AG
Dr. Hans Joachim Dürr
Head of Corporate Communications
Goethestrasse 26-28
60313 Frankfurt/Main
P: +49 69-21 93 96 111
F: +49 69-21 93 96 150

Copyright © Nanostart AG

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Iranian Experts Clean Uranium-Contaminated Water by Nano-Particles November 23rd, 2014

Novel Method Found for Connection of Metallic Alloys to Polymers November 23rd, 2014

New research project supports internationalisation in nano-research: Launch of new “Baltic Sea Network” November 22nd, 2014

3rd Iran-Proposed Nano Standard Approved by International Standard Organization November 22nd, 2014

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Eight19 secures £1m funding: Investment to develop production technology, and expand commercial activities for organic photovoltaics November 19th, 2014

Harris & Harris Group Reports Financial Statements as of September 30, 2014 November 11th, 2014

Harris & Harris Group to Host Conference Call on Third Quarter 2014 Financial Results on November 12, 2014 November 3rd, 2014

TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014

Investments/IPO's/Splits

Nanometrics Announces Upcoming Investor Events November 19th, 2014

Eight19 secures £1m funding: Investment to develop production technology, and expand commercial activities for organic photovoltaics November 19th, 2014

Arrowhead to Present at Upcoming Conferences November 15th, 2014

Harris & Harris Group Reports Financial Statements as of September 30, 2014 November 11th, 2014

Nanomedicine

New research project supports internationalisation in nano-research: Launch of new “Baltic Sea Network” November 22nd, 2014

Quantum mechanical calculations reveal the hidden states of enzyme active sites November 20th, 2014

Silver Nanoparticles Produced in Iran from Forest Plants Extract November 20th, 2014

Tokyo Institute of Technology research: Protein-engineered cages aid studies of cell functions November 19th, 2014

Announcements

Iranian Experts Clean Uranium-Contaminated Water by Nano-Particles November 23rd, 2014

Novel Method Found for Connection of Metallic Alloys to Polymers November 23rd, 2014

New research project supports internationalisation in nano-research: Launch of new “Baltic Sea Network” November 22nd, 2014

3rd Iran-Proposed Nano Standard Approved by International Standard Organization November 22nd, 2014

Appointments/Promotions/New hires/Resignations/Deaths

Mining entrepreneur Julian Malnic Joins Deep Space Industries’ Board: Deep Space Industries welcomes a prolific mining entrepreneur and accomplished company builder, Julian Malnic, to its Board of Directors November 14th, 2014

SEMATECH Names Ronald Goldblatt Permanent Chief Executive Officer November 7th, 2014

First Canada Excellence Research Chair gets $10 million from the federal government for oilsands research at the University of Calgary: Federal government announces prestigious research chair to study improving oil production efficiency October 19th, 2014

VDMA photonics steering committee with new members stronger than ever October 14th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More












ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE